Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT04977076
Recruiting Not applicable

Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention

NCT04977076 · tracked via the Priya Life Science Netherlands tracker
Phase
Not applicable
Started
2022-09-01
Last updated
2026-05-29

Condition(s) studied

Atrial FibrillationCoronary Artery DiseaseAnticoagulants

Investigational drug(s) / intervention(s)

Uninterrupted DOAC useInterrupted DOAC use

Uninterrupted DOAC use: Continuing DOAC use in advance of elective ICA or PCI.

Interrupted DOAC use: Usual care, interruption of DOAC prior to procedure.

Study summary

A prospective, multicenter, 1:1 randomized, investigator initiated study. Goal of this study is to examine the safety of uninterrupted periprocedural DOAC use.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients aged \>18 years using DOAC and undergoing elective ICA or PCI. * Provided signed informed consent Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: Any of the following: * Patients initially presenting with Acute Coronary Syndrome (STEMI, NSTEMI, UA) * Patients \<18 years old * Calculated creatinine clearance \<30 mL/min * Patients simultaneously participating in another clinical trial * History or condition associated with increased bleeding risk, as listed below: * Major surgical procedure within 30 days before the procedure * Known inaccessible radial artery during previous procedure * History of GI bleeding in the previous 6 months * History of intracranial, intraocular, spinal, or atraumatic intra-articular bleeding * Chronic bleeding disorder * Known intracranial neoplasm, arteriovenous malformation, or aneurysm * Known anemia with last measured haemoglobin value \<6 mmol/L \[9.67 g/dL\] * Current pregnancy or breast-feeding * Known significant liver disease (e.g., acute clinical hepatitis, chronic active hepatitis, cirrhosis), or Alanine aminotransferase (ALT) \>3 x the upper limit of normal. * Participation in another clinical trial

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zuyderland MC Heerlen Limburg Recruiting

More Zuyderland Medisch Centrum trials in the Netherlands

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04977076 on ClinicalTrials.gov ↗ ← All trials in the Netherlands